miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 16, 2026

Bitcoin Depot (BTM) Q4 2025 Earnings Transcript

View original at finance.yahoo.com
Bitcoin Depot (BTM) Q4 2025 Earnings Transcript Image source: The Motley Fool. DATE Monday, Mar. 16, 2026 at 10 a.m…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bitcoin Depot Inc. is best positioned to navigate evolving regulatory environment as largest operator in North America with one of the most robust compliance programs

    60% confidence
  • 2027 should be much less regulatory activity, though could be some revisions to existing state bills

    60% confidence
  • Can accelerate Cut growth substantially by investing more into marketing and engineering teams

    60% confidence
  • Currently do not anticipate further expansion of profit share program moving forward

    60% confidence
  • Do not know exactly what regulatory changes will happen in 2026, states will pass additional measures limiting economics but uncertain how many states or what bills will pass

    60% confidence
  • Q4 results declined year over year primarily driven by recently enacted state regulations that introduced transaction size caps and enhancements to compliance standards

    60% confidence
  • Have not seen changes internationally like what is happening in U.S., still actively working on two more countries to launch in late Q1 or early Q2

    60% confidence
  • 2026 is likely to be a challenging year for core BTM business with revenue expected to decline between 30% to 40% year over year

    60% confidence
  • Number of kiosks will likely stay flat or down slightly depending on how relocations are handled for states that pass particularly negative bills

    60% confidence
  • Users who have completed at least one transaction between 2016 and 12/31/2025 have transacted a total of $5,311 on average, up 5% from previous year

    60% confidence
  • Regulatory measures ultimately raise industry standards and reinforce advantages of scale, compliance infrastructure, and regulatory engagement

    60% confidence
  • By end of 2026, will have seen 80% to 90% of states decide where their stance is on regulation, at least initially

    60% confidence
  • 2025 was a strong year for Bitcoin Depot Inc. with growth across the majority of key operating and financial metrics and meaningful progress executing on long-term strategy

    60% confidence
  • Cut and ReadyBox represent important steps in evolution from single-product operator into broader fintech platform

    60% confidence
  • Do not expect Cut and ReadyBox to have material impact on overall revenue in current year

    60% confidence
  • Cut revenue will definitely be below $5 million for 2026

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Bitcoin Depot (BTM) Q4 2025 Earnings Transcript — Source | Via News | es.VIA.NEWS